WuXi Biologics (Cayman) (HKSE:02269) Debt-to-Revenue : 0.25 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$2,796 Mil. WuXi Biologics (Cayman)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$2,478 Mil. WuXi Biologics (Cayman)'s annualized Revenue for the quarter that ended in Dec. 2024 was HK$21,569 Mil. WuXi Biologics (Cayman)'s annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.24.

WuXi Biologics (Cayman) Debt-to-Revenue Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Debt-to-Revenue Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.59

0.42

0.29

0.27

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.27	0.30	0.27	0.27	0.25

Competitive Comparison of WuXi Biologics (Cayman)'s Debt-to-Revenue

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

WuXi Biologics (Cayman) Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

WuXi Biologics (Cayman)'s Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2796.24	+	2477.899)	/	19939.172
	=	0.26

WuXi Biologics (Cayman)'s annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2796.24	+	2477.899)	/	21569.446
	=	0.24

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.

WuXi Biologics (Cayman) Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

Executives

Li Ge	2201 Interest of corporation controlled by you
Liu Xiaozhong	2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited	2201 Interest of corporation controlled by you
New Wuxi Life Science Limited	2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited	2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc.	2201 Interest of corporation controlled by you
Zhang Zhaohui	2401 A concert party to an agreement to buy shares
Blackrock, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Brown Brothers Harriman & Co.	2502 Approved lending agent
Zhao Ning	2202 Interest of your spouse
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines